Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy

Conditions

• Myelodysplastic Syndromes
• Leukemia, Myeloid, Acute

Interventions

• OTHER: DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
• OTHER: DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice

Sponsor

King's College Hospital NHS Trust